$ACOG A-1062 helps with TBI and Alzheimer's 12% of people from 80-85 are diagnosed with dementia (including Alzheimer's).Source: https://www.canada.ca/en/public-health/services/publications/diseases-conditions/dementia-highlights-canadian-chronic-disease-surveillance.html
There already is a huge demand for Alzheimer's treatment and that demand will only be growing as the population ages.
Alpha Cognition ( $ACOG.V $ACOGF ) is a biopharmaceutical company that is developing medication for Alzheimer's, ALS, and other neurodegenerative disorders.
$ACOG's ALPHA-1062 drug, which has been shown to help with the effects of Alzheimer's, was also found to help with traumatic brain injury.
The drug reduced the extent of functional deficits and improved functional recovery of animals with TBIs.
This study displays the diversity of what ALPHA-1062 can be used for. (read more on this study here: https://finance.yahoo.com/news/alpha-cognition-announce-data-pre-140000753.html)
Their ALS focused medication is also looking very promising and I would highly suggest reading about it here: https://www.alphacognition.com/our-approach/alpha-0602/)
Right now $ACOG is trading at just $1.17, MC $71.951M